ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aumolertinib

Also written as “Almonertinib”, “Aumolertinib” and “HS-10296”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 4 companies.

Drug pageAumolertinib: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 23, 201815 company-led studies, 8 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group85 open or runningphase 3since Nov 23, 2018Nov 28, 2016none ahead
Jiangsu HengRui Medicineits history only43 open or runningphase 3since Sep 12, 2025Apr 2, 2019Jul 30, 2027phase 2 · NCT05503888
EQRx Internationalits history only20 open or runningphase 3since Jun 24, 2022Nov 5, 2021none ahead
Revolution Medicinesits history only10 open or runningphase 1since Jul 13, 2021Jul 13, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hansoh Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 28, 2016First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT02981108 · 364 enrolled · United States
  2. Nov 23, 2018Phase 3 study in Carcinoma, Non-Small-Cell LungNCT03849768 · 429 enrolled · China
  3. Dec 19, 2020Named aumolertinibINNProposed as its International Nonproprietary Name in WHO's List 124 · before, HS-10296
  4. Dec 23, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04687241 · 192 enrolled · China
  5. Jun 10, 20213 phase 3 studies in Carcinoma, Non-Small-Cell LungNCT04923906, NCT04951648, NCT04951635
  6. Oct 24, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06110663 · 314 planned
  7. Jul 31, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07130916 · 20 planned · Bosnia and Herzegovina, Bulgaria, Moldova

TargetBeta

EGFR →read by rule
“An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 8 Hansoh Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07130916Carcinoma, Non-Small-Cell Lung · Bosnia and Herzegovina, Bulgaria, Moldova1RecruitingAug 9, 202520
NCT06110663Carcinoma, Non-Small-Cell Lung3Not yet recruitingDec 30, 2024314
NCT04951648Carcinoma, Non-Small-Cell Lung · China3UNKNOWNOct 4, 2023220
NCT04951635Carcinoma, Non-Small-Cell Lung · China3RecruitingJul 15, 2024150
NCT04923906Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingJun 18, 2024624
NCT04687241Carcinoma, Non-Small-Cell Lung · China3Active, not recruitingJul 8, 2024192
NCT03849768Carcinoma, Non-Small-Cell Lung · China3UNKNOWNJan 15, 2021429
NCT02981108Carcinoma, Non-Small-Cell Lung · United States2UNKNOWNJan 5, 2019364

How it is read

Names in the registry

  • “Almonertinib”, 3 entries
  • “Aumolertinib”, 2 entries
  • “aumolertinib”, 2 entries
  • “HS-10296”, 2 entries
  • “almonertinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.